CTL019
Phase 3RecruitingInterest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
B-cell Acute Lymphoblastic Leukemia
Conditions
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
Trial Timeline
Nov 21, 2019 → Apr 27, 2027
NCT ID
NCT04094311About CTL019
CTL019 is a phase 3 stage product being developed by Novartis for B-cell Acute Lymphoblastic Leukemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04094311. Target conditions include B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma.
What happened to similar drugs?
3 of 20 similar drugs in B-cell Acute Lymphoblastic Leukemia were approved
Approved (3) Terminated (2) Active (15)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03601442 | Pre-clinical | Active |
| NCT04161118 | Phase 2 | Terminated |
| NCT04094311 | Phase 3 | Recruiting |
| NCT03876769 | Phase 2 | Active |
| NCT03123939 | Phase 3 | Completed |
| NCT02435849 | Phase 2 | Completed |
Competing Products
20 competing products in B-cell Acute Lymphoblastic Leukemia